Compare LGL & BSEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGL | BSEM |
|---|---|---|
| Founded | 1917 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.0M | 76.9M |
| IPO Year | 2017 | 2026 |
| Metric | LGL | BSEM |
|---|---|---|
| Price | $6.85 | $3.71 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.0K | ★ 136.7K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,169,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.45 | $2.25 |
| 52 Week High | $7.88 | $5.44 |
| Indicator | LGL | BSEM |
|---|---|---|
| Relative Strength Index (RSI) | 43.59 | 49.99 |
| Support Level | $6.63 | $3.69 |
| Resistance Level | $7.34 | $4.65 |
| Average True Range (ATR) | 0.24 | 0.46 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 39.96 | 17.56 |
LGL Group Inc is a holding company engaged in services, merchant investment, and manufacturing business activities. The company has two reportable segments: Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications, including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.